Negotiating limits to the funding of high cost cancer medicines by Lipworth, W et al.
93
ETHICS IN CANCER
NEGOTIATING LIMITS TO THE FUNDING OF HIGH 
COST CANCER MEDICINES
 
Abstract
The cost of pharmaceuticals is overwhelming health budgets around the world. A growing proportion of this burden 
stems from the ever-increasing demand for subsidisation of cancer medicines. Those making decisions about 
which cancer medicines should be subsidised are often criticised by patients, clinicians and the pharmaceutical 
industry for withholding life-saving treatments from patients in desperate need. While their arguments are 
emotionally compelling, these critics often fail to recognise the complexity of resource allocation decisions, and 
the challenges faced by those making such decisions. In this article we describe two of these challenges: 1) the 
need for decision-makers to balance their desire to rescue those in desperate need against their responsibility to 
consider population-level opportunity costs and to make decisions based on solid evidence of cost-effectiveness; 
and 2) their need to negotiate ‘fair’ prices for medicines when they lack negotiating power, and when prices 
seem to be more reflective of what the ‘market will bear’ than what the medicines are really ‘worth’. We conclude 
that, while there is no easy solution to these challenges, there is a need for greater transparency and procedural 
fairness, so that stakeholders are both more alert to the complexity of decisions about funding high cost cancer 
medicines, and more willing to accept the outcomes of these decisions.
Cancer is one of the most active areas of contemporary 
drug development. According to the Pharmaceutical 
Research and Manufacturers of America, there are 98 
drugs currently being developed for lung cancer, 87 for 
leukemia, 78 for lymphoma, 73 for breast cancer, 56 
for skin cancer and 48 for ovarian cancer. In total, 3137 
clinical trials for cancer drugs are being conducted in 
the US alone.1 Patients and clinicians often have high 
hopes that these new cancer therapies will be safe and 
effective, particularly because many of these medicines 
are ‘targeted’, or ‘personalised’ and therefore appear to 
be ‘designed’ with particular patients in mind.2 Success 
stories, such as imatinib for chronic myeloid leukemia,3 
and trastuzumab for early, that is, non-metastatic, breast 
cancer,4 bolster these hopes. 
Driven by this optimism, patients and clinicians focus 
much of their attention on the need for regulators to 
approve cancer therapies as quickly as possible, and 
for public and private insurers (henceforth ‘payers’) to 
subsidise them.5,6 Governments have responded to this 
demand by establishing programs such as the UK’s 
Cancer Drugs Fund,7 and Australia’s Herceptin Program,8 
which provide access to cancer medicines that have 
not been deemed to be cost-effective according to the 
usual standards applied by organisations such as the 
UK’s National Institute for Health and Care Excellence or 
Australia’s Pharmaceutical Benefits Advisory Committee. 
In Australia, growing expectations for access to expensive 
cancer therapies has also led to increased pressure on 
hospital therapeutics committees to provide access to 
expensive cancer medicines that are not listed on the 
Pharmaceutical Benefits Scheme or, alternatively, on 
the pharmaceutical industry to provide ‘compassionate 
access’ (also referred to as ‘patient access’, 
‘compassionate use’, ‘named patient’ and ‘expanded 
access’), which makes cancer medicines available, 
either for free or at a discount, to patients who meet 
specific inclusion criteria.9 For example, for hematological 
malignancies, approximately 21% of patients receive 
non-Pharmaceutical Benefits Scheme funded drugs. Of 
these, 31% receive access through industry or hospitals, 
61% through clinical trials, and 37% have to draw on 
savings, sell assets, take out loans, or fundraise to help 
pay for their treatments.10
There has also been a recent growth in calls for ‘coverage 
with evidence development’, a type of ‘managed entry’ 
in which payers subsidise cancer therapies that have 
not been conclusively demonstrated to be safe and/
or effective, with a view to subsequently generating 
evidence to support either ongoing subsidisation or 
disinvestment. Coverage with evidence development 
arrangements is already in place for selected cancer 
therapies in the US, UK, Europe and Australia.11 
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Complexity and conflict in decisions about 
access to cancer medicine
There is of course, nothing wrong with patients and 
clinicians lobbying for access to cancer therapies, or with 
policymakers changing their processes to facilitate such 
access. But health systems globally are struggling to cope 
with this demand. A prediction that global spending on 
cancer medicines would reach $100 billion by 2018 saw 
this threshold passed in 2014, with almost 50% of this 
spending associated with new, targeted therapies.12,13 
The economic challenges associated with funding cancer 
medicines are evident in the recent streamlining of the 
UK Cancer Drugs Fund,14 and ongoing concerns about 
its viability.15 Similar concerns have been expressed 
about Australia’s capacity to cope with the growing 
demand for cancer medicines, with a recent Senate report 
acknowledging that expensive cancer medicines are a 
major challenge for governments attempting to balance 
affordable access while maintaining a sustainable health 
budget.16
Given the strain placed on health systems by cancer 
medicines, it is crucial that those advocating for access 
to cancer medicines have a sophisticated understanding 
of the values that regulators and payers have to consider 
when they make their decisions. That they have a good 
understanding of why cancer medicines cost what they 
do, and why it can be so difficult for payers to negotiate 
fair prices is also important.
Competing values in decisions about access to 
cancer medicines
Those making these decisions about access to cancer 
medicines need to contend with a number of competing 
moral, clinical, economic and scientific values. Broadly 
speaking, these can be summarised as the desire to:
1. provide benefit to patients, without harming them, 
and to fulfill the related ‘rule of rescue’, which is the 
moral and psychological imperative to help those 
in desperate need, irrespective of cost or scientific 
uncertainty;17 
2. achieve equity - that is, ensuring that patients are not 
disadvantaged simply because they have rare cancers 
or, in the case of targeted cancer therapies, rare 
subsets of cancers; 
3. allocate resources efficiently - that is, producing 
the ‘greatest good for the greatest number’ in an 
affordable and cost-effective manner, and paying a 
‘fair’ price for medicines, based on their clinical value; 
and   
4. make decisions based on sound scientific evidence of 
effectiveness, safety and cost-effectiveness.
Each of these values can be particularly difficult to fulfill 
in relation to cancer medicines. First, cancer medicines 
are not always as safe and effective as hoped. In many 
cases, decisions to provide access to cancer medicines 
are based on surrogate outcomes such as progression-
free survival,18 so prediction of their true clinical benefit 
can be difficult. Cancer medicines also have serious and 
costly side-effects. For instance, up to 22% of cancer 
patients treated with chemotherapy are estimated to 
require hospitalisation for neutropenia.19 Even targeted 
cancer therapies, which are touted as being both safer 
and more effective than standard chemotherapies have 
their risks. For example, trastuzumab has been found to 
be associated with serious cardiotoxicity when combined 
with adjuvant chemotherapy.20 
Efficiency and affordability can be difficult to achieve 
because, as discussed above, cancer therapies are often 
so expensive, stretching health systems to their limits, and 
creating enormous opportunity costs. Achieving equity 
can also be challenging because, unless medicines are 
subsidised nationally, access to medicines is contingent 
on ad hoc decision-making by hospital therapeutics 
committees or by pharmaceutical companies.9 In the 
absence of these mechanisms, only the wealthiest 
patients, or those with the necessary connections for 
personal fundraising, can afford to pay for their own 
cancer therapies.
The desire to make decisions based on sound scientific 
evidence of effectiveness, safety and cost effectiveness, 
that is, to adhere to the principles of evidence-based 
medicine, can also be extremely challenging in relation to 
cancer medicines. One reason for this is that patients are 
often desperately ill and are often not willing to be subjected 
to the ‘control’ treatment in cancer clinical trials, or want 
to ‘crossover’ to the active treatment when their disease 
progresses.21,22 The increasing number of targeted cancer 
therapies in development exacerbates these difficulties 
because there is often a lack of evidence of their safety 
and efficacy from systematic reviews and meta-analyses 
of large, placebo-controlled randomised control trials 
(RCTs). This is primarily because RCTs and meta-analyses 
of targeted therapies can only be conducted when 
diseases and/or biomarkers are common, exemplified by 
the BCR-ABL translocation in chronic myeloid leukaemia, 
the HER-2 mutation in breast cancer or the EGFR 
mutations in lung cancer.23-26 In many cases, however, 
populations with specific biological profiles are very small, 
which means that, unless effect sizes are very large, 
the conduct of trials of targeted therapies comparable 
in power to the standards demanded by conventional 
RCTs can be challenging. There are also a number of 
other challenges associated with conducting RCTs of 
targeted cancer therapies, including the need to evaluate 
companion diagnostics alongside targeted therapies, and 
the difficulties associated with determining which patient 
group to select as the comparator in trials of targeted 
therapies.21,22 While there is currently a concerted effort to 
develop epidemiological and statistical methods for dealing 
with these challenges,21,22,27,28 regulators and payers are 
still challenged by calls to soften their commitment to the 
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principles of evidence-based medicine in order to allow 
access to targeted cancer therapies.29
The abovementioned moral, clinical, economic and 
scientific principles are not only difficult to achieve in 
isolation, but can also be in tension with each other. 
These tensions are evident in the frequent news reports 
of patients who have been ‘refused’ access to the ‘only’ 
cancer therapy that could have ‘saved their life’.30,31 In 
these accounts, narratives of benefit, rescue and equity 
are typically countered by arguments about avoiding 
harm, ensuring affordability and cost-effectiveness, and 
adhering to the principles of evidence-based medicine. 
Similar competing principles are evident in the efforts of 
some pharmaceutical companies and disease advocacy 
groups to persuade regulators and payers to be more 
supportive of cancer medicines, and to facilitate access to 
them even if they are not, or have not been shown through 
RCTs to be, effective or ‘cost-effective’ according to the 
criteria usually used by regulators and payers.5,32
The challenges of negotiating fair prices for cancer 
medicines
While those conducting health technology assessments 
of high cost cancer medicines have traditionally focused 
most of their attention on evidence of effectiveness and 
cost-effectiveness, payers are becoming increasingly 
concerned about the price of new cancer medicines. One 
example of a high cost cancer medicine recently approved 
is pembrolizumab (Keytruda), used to treat patients with 
melanoma, which is expected to cost approximately 
US$120,000 per patient per year.33,34  
While payers who question high drug prices are often 
criticised by the pharmaceutical industry for being naïve 
about the costs associated with drug development, they 
are in fact more concerned about whether the prices 
being asked for new medicines are ‘fair’. In this context, a 
fair price is one that reflects the amount that a company 
needs to charge in order to for it to recoup the costs of 
drug development, continue to innovate, and make a 
reasonable profit for its shareholders. 
Payers who want to negotiate such fair prices find 
themselves in a difficult position because there is currently 
no agreement as to how much development really costs a 
new medicine. Researchers from the Boston-based Tufts 
University Centre for the Study of Drug Development have 
recently estimated that it costs $2.6 billion to bring a new 
drug to market, with $1.4 billion attributed to direct costs 
of development and $1.2 billion attributed to investment 
returns necessary to attract investors. This estimate also 
accounts for drugs that have failed at some stage during 
development.35 This figure has, however, been contested 
by a number of people who claim that it does not account 
for public contributions to R&D, exaggerates the return 
on investment required to attract investment, and ignores 
experience showing that drugs can be developed for 
much less than the Tufts figure suggests.36,37
In addition, although pharmaceutical companies often 
complain about the enormous risks and costs they bear, 
the industry remains highly profitable in comparison to 
other industries highly dependent on R&D, while up to 
three to 37 times more profitable according to some.38 
Only 1.3% and 13% of revenue is channelled back into 
basic and clinical research respectively.39 There is, of 
course, nothing wrong with companies making profits, 
but the pharmaceutical industry receives extensive public 
support in the form of incentives and tax breaks. In return 
for this, there is the expectation that the industry will not 
exploit its success, but many people question whether 
the pharmaceutical industry is upholding its end of the 
bargain.
Sceptics thus believe that medicines are priced not 
according to what they cost to develop or what would 
constitute a fair return to shareholders, but rather according 
to what the ‘market will bear’.40 Given that the market for 
cancer medicines is dominated by a few regions, most 
notably the US and Europe, and characterised by lack 
of consumer autonomy, unlike other consumer goods, 
patients cannot simply choose whether to partake of 
cancer therapy, price insensitivity on the part of patients 
and clinicians,41 and information asymmetry regarding the 
cost of developing medicines, simply ‘letting the market 
work’ does not necessarily lead to fair prices for cancer 
medicines. 
Negotiating limits to the funding of high 
cost cancer medicines
When values conflict and there is no obvious means of 
resolving them, and when policy decisions are complex, 
focusing on procedural justice becomes extremely 
important. This entails educating all stakeholders so 
they can participate in, and critique decision-making. It 
also entails having clear frameworks in place for specific 
decisions. A useful framework that can be applied is that 
of  ‘accountability for reasonableness’, which emphasises 
1) public access to decisions and transparency about 
reasons for decisions (publicity);  2) relevance of reasons 
to ‘fair minded’ participants (relevance); 3) mechanisms 
for challenging or disputing decisions (appeals); and 4) 
regulation of the process (enforcement).42 
For such a process to be possible for the funding of 
high cost cancer medicines, far greater transparency 
will be required. At present, decisions about access 
to cancer medicines are often not made transparently, 
largely because of the perceived need to maintain 
commercial confidentiality.43 While it is understandable 
that companies would not want to completely reveal their 
commercial interests, especially about prices, without 
greater openness,43 it may be impossible to achieve 
accountability for reasonableness and, rightly or wrongly, 
people will be left with the feeling that their values are not 
being respected.
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Conclusion
New cancer medicines hold great promise, but the 
demand for these medicines places enormous strain on 
health systems. Those making decisions about funding 
cancer medicines face two key challenges: 1) balancing 
their desire to rescue those in desperate need with their 
responsibility to make decisions based on solid evidence 
of cost-effectiveness and to consider population-level 
opportunity costs; and 2) their need to negotiate fair prices 
for medicines when they lack negotiating power and when 
prices seem to be more reflective of what the market will 
bear than what the medicines are really worth. If their 
decisions are to be understood and have legitimacy, then 
they need to adhere to the principles of procedural justice 
and ‘accountability for reasonableness.’ As a starting 
point, companies and payers will need to be far more 
transparent about both the cost of drug development and 
the process of resource allocation.
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